首页> 外文期刊>Hepatology communications. >Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
【24h】

Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis

机译:肝癌中肝癌的肝癌的发生率和危险因素的肝硬化队列

获取原文
           

摘要

Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis and Part D prescription coverage from 2008 to 2014. We modelled incident HE using demographic, clinical, and pharmacologic data. Risk factors for HE were evaluated, including demographics/socioeconomics, cirrhosis etiology, severity of liver disease, and pharmacotherapy, along with gastroenterology consultation, as time‐varying covariates. Among 166,192 Medicare enrollees with cirrhosis followed for 5.25 (interquartile range [IQR], 2.00‐7.00) years, the overall incidence of HE was 11.6 per 100 patient‐years. The cohort's median age was 65?years (IQR, 57‐72), 31% had alcohol‐related cirrhosis, and 49% had likely nonalcoholic fatty liver disease cirrhosis. The two strongest associations with HE were alcohol‐related cirrhosis (adjusted hazard ratio [AHR], 1.44; 95% confidence interval [CI], 1.40, 1.47, relative to nonalcoholic nonviral cirrhosis) and the presence of portal hypertension (AHR, 3.42; 95% CI, 3.34, 3.50). Adjusting for confounders, benzodiazepines (AHR, 1.24; 95% CI, 1.21, 1.27), gamma aminobutyric acid (GABA)ergics (AHR, 1.17; 95% CI, 1.14, 1.21), opioids (AHR, 1.24; 95% CI, 1.21, 1.27), and proton pump inhibitors (PPIs) (AHR, 1.41; 95% CI, 1.38, 1.45) were all associated with incident HE. Only benzodiazepines, however, were associated with the risk of hospitalization with HE (incidence‐rate ratio, 1.23; 95% CI, 1.20, 1.26). Conclusion: Novel data regarding the risk of HE for contemporary patients with cirrhosis are provided. The incidence of HE in an older population of Americans with cirrhosis is high, particularly among those with alcohol‐related cirrhosis and portal hypertension. Several medication classes, namely PPIs, opiates, GABAergics, and benzodiazepines, represent potentially modifiable risk factors for HE.
机译:肝脏脑病(他)是肝硬化的毁灭性并发症。关于当代患者在肝硬化流行病学的背景下,关于他在当代患者的发生率和风险因素的发生率有限。我们研究了2008年至2014年与肝硬化和第D部分处方覆盖的20%的U.S.Medicare登记册。我们使用人口统计学,临床和药理学数据建模了他的事件。他评估了他的风险因素,包括人口统计/社会经济,肝硬化病因,肝病严重程度以及药物治疗以及胃肠学咨询,作为胃肠学咨询,作为偶然的协变量。在166,192家Medicare入学中,肝硬化率为5.25(局部漫长范围[IQR],2.00-7.00)年,他的总体发病率为每100例患者年份。队列的中位数年龄为65岁?年(IQR,57-72),31%有含有酒精相关的肝硬化,49%可能有可能的非酒精性脂肪肝病肝硬化。与他的两个最强的联想是与酒精有关的肝硬化(调节危险比[AHR],1.44; 95%置信区间[CI],1.40,1.47,相对于非酒精非血管肝硬化和门骨高血压的存在(AHR,3.42; 95%CI,3.34,3.50)。调整混凝剂,苯二氮氧基化动物(AHR,1.24; 95%CI,1.21,1.27),γ氨基丁酸(GABA)ERGICS(AHR,1.17; 95%CI,1.14,1.21),阿片类药物(AHR,1.24; 95%CI, 1.21,1.27)和质子泵抑制剂(PPI)(AHR,1.41; 95%CI,1.38,1.45)都与事件有关。然而,只有苯并二氮杂化动物与他(发病率比,1.23; 95%CI,1.20,1.26)有关。结论:提供了关于他对肝硬化患者的风险的新数据。他在肝硬化的年龄较大的美国人群体中的发病率很高,特别是与酒精有关的肝硬化和门户高血压的人。几种药物课程,即PPI,Apiates,Gabaergics和苯并二氮杂卓,代表了他的潜在可修改的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号